« Return to News | R&D Trends

Covance to be exclusive drug development provider for BioPontis

Friday, February 3, 2012 01:25 PM

Covance has signed a three-year, exclusive integrated drug development agreement with BioPontis Alliance to manage early development of scientific discoveries from academia. Covance will become BioPontis Alliance’s sole provider of drug development services, including discovery support, pre-clinical, bioanalytical, CMC, clinical, central labs and commercialization.

“We are excited to take this unprecedented step forward with Covance as our translational development partner,” said Richard Basile, CEO and principal of BioPontis Alliance. “Together, with our university and industry partners, we have established a new development model to fuel biopharma’s early stage pipeline and accelerate the availability of new medicines.”


In this unique early development model, Covance will integrate and manage the services required to move a compound from lead optimization into the clinic, providing the scientific and operational continuity that reduces the feasibility gap between academic intellectual property and human proof of concept.

“Designing customized solutions that meet the unique needs of each client is the hallmark of our partnering philosophy,” said John Watson, chief commercial officer and president, strategic partnering, Covance. “This collaboration creates a new way for Covance to leverage our scientific expertise and broad portfolio of drug development services to advance the promising science of academia and deliver greater medical innovation to the biopharmaceutical industry.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.